Effect of a biomimetic pathogen adsorbing device on inflammatory biomarkers in COVID‐19 patients-Reference-Cited by-同舟云学术

Effect of a biomimetic pathogen adsorbing device on inflammatory biomarkers in COVID‐19 patients

Published:2024-05-12 Issue:5 Volume:28 Page:802-809
ISSN:1744-9979
Container-title:Therapeutic Apheresis and Dialysis
language:en
Short-container-title:Ther Apher Dial

Author:

Schmieszek Jan¹,Fuehner Thomas¹²^ORCID,Renger Isabelle¹,Welte Tobias²,Menne Jan³,Fuge Jan²,van't Klooster Maria P.¹^ORCID,Paul Andrea¹,Siegert Alina⁴,Borchina Dan‐Nicolae⁴,Falk Christine S.⁵,Kielstein Jan T.⁴^ORCID

Affiliation:

1. Department of Respiratory Sleep and Intensive Care Medicine, Siloah Hospital Hannover Germany

2. Department of Respiratory Medicine and German Centre for Lung Research (DZL/BREATH) Hannover Medical School Hannover Germany

3. Department of Nephrology, Angiology, and Rheumatology Siloah Hospital Hannover Germany

4. Department of Nephrology, Rheumatology, Blood Purification Academic Teaching Hospital Braunschweig Braunschweig Germany

5. Institute of Transplant Immunology, Hannover Medical School Hannover Germany

Abstract

AbstractIntroductionThe Seraph 100 Microbind Affinity blood filter eliminate bacteria, viruses, fungi and toxins from blood stream.MethodsThis is a prospective multicenter observational biomarker trial in PCR‐positive SARS‐CoV‐2 patients with acute respiratory failure. Biomarkers were sequentially tested at three time points.ResultsForty‐two patients with SARS‐CoV‐2 detected by PCR with acute respiratory failure were included. When receiving hemoperfusion treatment, 27 (64%) patients were on mechanical ventilation, 41 (98%) patients were treated in the ICU. The 3‐month survival was 52%. After one hemoperfusion treatment cycle, D‐dimer (p = 0.014), hemoglobin (p = 0.003) and LDH (p = 0.001) concentrations were significantly reduced 4 days after treatment. From the multiplex assay IL‐1b, CXCL8/ IL‐8, IL‐10, IL‐13, IL‐15, CCL11/Eotaxin, G‐CSF, and CXCL10/IP‐10 were significantly reduced 1 h after treatment, however not 4 days later.ConclusionHemoperfusion with Seraph 100 Microbind Affinity Filter in patients with severe COVID‐19 can transiently reduce several inflammatory biomarkers in the blood.

Publisher

Wiley

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/1744-9987.14137

Reference36 articles.

1. Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine

2. Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine

3. Fourth Dose of BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Setting

4. Dexamethasone in Hospitalized Patients with Covid-19

5. Oral Nirmatrelvir for High-Risk, Nonhospitalized Adults with Covid-19